At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
|Articles|July 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 7
- Volume 4
- Issue 7
Health-Related Legislation
S5755, an amendment (no. 603) introduced by Sen. McConnell (R-KY), to reform the health-care liability system and improve health-care quality through establishment of quality assurance programs, was agreed to by voice vote.
Advertisement
- S5755, an amendment (no. 603) introduced by Sen. McConnell(R-KY), to reform the health-care liability system and improvehealth-care quality through establishment of quality assuranceprograms, was agreed to by voice vote.
- S5793, an amendment (no. 605) introduced by Sen. Wellstone(D-MN), to revise provisions regarding reports on medical malpracticedata and access to certain information, was tabled by voice vote.
- S5800, an amendment (no. 608) introduced by Sen. Snowe (R-ME),to limit the amount of punitive damages that may be awarded ina health-care liability action, was agreed to by voice vote.
- S5931, an amendment (no. 611) introduced by Sen. Kyl (R-AZ),to place a limitation of $500,000 on noneconomic damages thatare awarded to compensate a claimant for pain, suffering, emotionaldistress, and other related injuries, was tabled by voice vote.
- H1566, a bill to amend the Internal Revenue Code to make permanentthe credit for clinical testing expenses for certain drugs andrare diseases or conditions was introduced by Rep. Johnson (R-CT).
Articles in this issue
over 31 years ago
House Panel Holds Hearing on Self-Referralover 31 years ago
Mitoguazone Appears Promising in HIV-Associated Refractory NHLover 31 years ago
Responses to Anti-HER2 MoAb Seenover 31 years ago
MoAb May Improve Detection of Colon And Rectal Cancerover 31 years ago
Zeneca Files NDA for Arimidexover 31 years ago
HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and AbuseAdvertisement
Related to this article
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5